$450M Convertible Notes Priced by Indivior, Includes $75M Share Buyback
Summary
Indivior Pharmaceuticals has priced its upsized offering of $450 million in 0.625% convertible senior notes due 2031, an increase from the previously announced $400 million. This financing event, which follows yesterday's proposed offering announcement, features a favorable 35% conversion premium over the current stock price. A significant aspect is the concurrent repurchase of approximately $75 million of common stock, which will help offset potential dilution from the notes. The net proceeds will primarily be used to repay existing debt, strengthening the company's capital structure, with the remainder allocated for general corporate purposes. Traders will monitor the settlement on March 17, 2026, and the overall impact on the company's financial leverage and share count.
At the time of this announcement, INDV was trading at $30.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $8.64 to $38.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.